Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer

• Published in: PloS one Vol. 8; no. 10; p. e75507
• Main Authors: Chu, Zhengtao, Abu-Baker, Shadi, Palascak, Mary B, Ahmad, Syed A, Franco, Robert S, Qi, Xiaoyang
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 04.10.2013; Public Library of Science (PLoS)
• Subjects: Acids; Animal models; Animals; Apoptosis; Biomarkers; Cancer; Cancer research; Cancer therapies; Cancer treatment; Carbon dioxide; Cell Line, Tumor; Cell survival; Chemotherapy; Cytotoxicity; Enzymes; Exposure; Female; Gene therapy; Health aspects; Hematology; Humans; Internal medicine; Lipids; Lysosomal protein; Medicine; Membranes; Mice; Mice, Nude; Nanoparticles - adverse effects; Nanoparticles - chemistry; Nanoparticles - metabolism; Neuroblastoma; Oncology; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - metabolism; Phosphatidylserine; Phosphatidylserines - chemistry; Phospholipids; Proteins; Saposins - chemistry; Signal transduction; Skin cancer; Survival; Toxicity; Tumor cells; Tumors; Xenografts; Xenotransplantation; United States > US; Ohio
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0075507

Only a small number of promising drugs target pancreatic cancer, which is the fourth leading cause of cancer deaths with a 5-year survival of less than 5%. Our goal is to develop a new biotherapeutic agent in which a lysosomal protein (saposin C, SapC) and a phospholipid (dioleoylphosphatidylserine, DOPS) are assembled into nanovesicles (SapC-DOPS) for treating pancreatic cancer. A distinguishing feature of SapC-DOPS nanovesicles is their high affinity for phosphatidylserine (PS) rich microdomains, which are abnormally exposed on the membrane surface of human pancreatic tumor cells. To evaluate the role of external cell PS, in vitro assays were used to correlate PS exposure and the cytotoxic effect of SapC-DOPS in human tumor and nontumorigenic pancreatic cells. Next, pancreatic tumor xenografts (orthotopic and subcutaneous models) were used for tumor targeting and therapeutic efficacy studies with systemic SapC-DOPS treatment. We observed that the nanovesicles selectively killed human pancreatic cancer cells in vitro by inducing apoptotic death, whereas untransformed cells remained unaffected. This in vitro cytotoxic effect correlated to the surface exposure level of PS on the tumor cells. Using xenografts, animals treated with SapC-DOPS showed clear survival benefits and their tumors shrank or disappeared. Furthermore, using a double-tracking method in live mice, we showed that the nanovesicles were specifically targeted to orthotopically-implanted, bioluminescent pancreatic tumors. These data suggest that the acidic phospholipid PS is a biomarker for pancreatic cancer that can be effectively targeted for therapy utilizing cancer-selective SapC-DOPS nanovesicles. This study provides convincing evidence in support of developing a new therapeutic approach to pancreatic cancer.